The Elderly and Diffuse Large B-cell Lymphoma

[Guest guest]

A comment article in the Lancet Oncology summarizes the

situation of treating very elderly patients for Diffuse

Large B-cell Lymphoma. This is seen as a Richter's

transformation in CLL or perhaps as a parallel cancer.

The author refers to a study by Peyrade and colleagues

published in this issue of The Lancet Oncology, which is the

first large phase 2 trial combining rituximab with dose-

reduced CHOP (R-miniCHOP).

A substantial response and survival benefit (2-year overall

survival 59%) was reported in selected patients over 80

years of age.

The study offers hope for very elderly patients with diffuse

large B-cell lymphoma-a group that is frequently excluded

from clinical trials-and this study constitutes a very good

starting point for future improvement in patient outcome.

This is a free article to read but you must sign up to read

it. It is Free to do so.

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970080-8/fu\

lltext

or

http://tinyurl.com/6xcxumk